Kyverna (NASDAQ: KYTX) director granted RSUs and stock options in new Form 4

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. director Beth C. Seidenberg reported equity compensation awards rather than open-market trading. She received 5,093 shares of common stock as a restricted stock unit grant, bringing her directly held common stock to 21,727 shares after the award.

She also received a stock option for 20,582 shares of common stock at an exercise price of $8.59 per share, all of which remain outstanding. Both the restricted stock units and the option will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholder meeting, assuming her continuous service.

Separately from these direct holdings, entities associated with Westlake BioPartners report indirect ownership of 869,317 shares and 3,787,940 shares of Kyverna common stock. Seidenberg has voting and dispositive control over the relevant general partners but disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider SEIDENBERG BETH C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,582	$0.00	--
Grant/Award	Common Stock	5,093	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 20,582 shares (Direct, null); Common Stock — 21,727 shares (Direct, null); Common Stock — 3,787,940 shares (Indirect, See Footnote)

Footnotes (1)

1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any. Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.

Key Figures

RSU grant size: 5,093 shares Option grant size: 20,582 shares Option exercise price: $8.59 per share +5 more

8 metrics

RSU grant size 5,093 shares Restricted stock unit award of common stock

Option grant size 20,582 shares Stock option covering common stock

Option exercise price $8.59 per share Stock option strike price

Direct common shares after grant 21,727 shares Beth Seidenberg direct Kyverna common stock

Westlake Fund I indirect holdings 869,317 shares Kyverna common stock held by Westlake BioPartners Fund I, L.P.

Westlake Opportunity Fund I holdings 3,787,940 shares Kyverna common stock held by Westlake BioPartners Opportunity Fund I, L.P.

Vesting date trigger May 27, 2027 Full vesting date alternative for RSUs and option

Option expiration May 27, 2036 Stock option expiration date

Key Terms

restricted stock unit, vest, stock option, pecuniary interest, +1 more

5 terms

restricted stock unit financial

"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vest financial

"will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

stock option financial

"All of the shares subject to the option shall be fully vested and exercisable on the earlier"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

pecuniary interest financial

"disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein"

dispositive control financial

"has sole voting and dispositive control over Westlake GP I"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEIDENBERG BETH C

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 200

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A		5,093(1)	A	$0	21,727	D
Common Stock								3,787,940	I	See Footnote(3)
Common Stock								869,317	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.59	05/27/2026		A		20,582		(2)	05/27/2036	Common Stock	20,582	$0	20,582	D

Explanation of Responses:

1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

2. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

3. Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.

4. Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.

	By: /s/ Samantha H. Eldredge, as Attorney-in-fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Beth C. Seidenberg report in this Kyverna (KYTX) Form 4?

Beth C. Seidenberg reported a grant of 5,093 restricted stock units and a stock option for 20,582 Kyverna common shares at a $8.59 exercise price. These awards represent equity compensation rather than open-market purchases or sales of KYTX stock.

What are the vesting terms of Beth Seidenberg’s new Kyverna (KYTX) equity awards?

Both the 5,093 restricted stock units and the 20,582-share stock option will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholder meeting, provided Seidenberg remains in continuous service to the company through the applicable vesting date.

How many Kyverna (KYTX) shares does Beth Seidenberg hold directly after these awards?

After receiving the 5,093-share restricted stock grant, Beth Seidenberg directly holds 21,727 Kyverna common shares. This figure reflects her personal direct ownership reported in the Form 4 and does not include additional indirect holdings through Westlake BioPartners investment funds.

What indirect Kyverna (KYTX) holdings are associated with Westlake BioPartners funds?

The filing lists 869,317 Kyverna shares held by Westlake BioPartners Fund I, L.P. and 3,787,940 shares held by Westlake BioPartners Opportunity Fund I, L.P. Seidenberg manages the general partners, has voting and dispositive control, but disclaims beneficial ownership beyond any pecuniary interest.

Does this Kyverna (KYTX) Form 4 show Beth Seidenberg buying or selling shares on the market?

The Form 4 does not show open-market buying or selling by Beth Seidenberg. Instead, it reports equity compensation: a restricted stock unit grant of 5,093 shares and a 20,582-share stock option award, both subject to future vesting conditions tied to continued service.

What is the exercise price and expiration date of Beth Seidenberg’s Kyverna (KYTX) stock option?

Beth Seidenberg’s new Kyverna stock option covers 20,582 common shares at an exercise price of $8.59 per share. All shares under the option will be fully vested by the earlier of May 27, 2027, or the 2027 stockholder meeting, and the option expires on May 27, 2036.